Cancer Diagnosis by Multiplex Protein Epitope Profiling

Información del proyecto

CANDLE

Identificador del acuerdo de subvención: 697211

DOI

10.3030/697211

Proyecto cerrado

Fecha de la firma de la CE 26 Agosto 2015

Fecha de inicio 1 Septiembre 2015

Fecha de finalización 31 Octubre 2015

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

BIOSYSTEMS INTERNATIONAL KUTATO-, FEJLESZTO-, HASZNOSITO ES SZOLGALTATO KFT
Hungary

Periodic Reporting for period 1 - CANDLE (Cancer Diagnosis by Multiplex Protein Epitope Profiling)

Período documentado: 2015-09-01 hasta 2015-10-31

Resumen del contexto y de los objetivos generales del proyecto

Cancer incidence is continuously increasing, making it a major concern of European governments. Cheaper, more sensitive and specific diagnostic tests are needed to foster early cancer diagnosis, thereby alleviating the impact of cancer on citizens’ lives and reducing overall cancer care costs. Biosystems International Kft. (BSI) developed a diagnostics technology based on plasma protein epitome biomarker panels, with promising results to meet these needs for breast (BC) and colon (CC) cancers. BSI’s novel biomarkers-based in vitro diagnostics will bring better health outcomes for the patient as earlier detection will increase survival and will reduce overall care costs contributing to the sustainability of the health care system.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

In Phase I of CANDLE, BSI consolidated the business plan incorporating thorough market and commercialization studies for BC and CC and conducted a technology intellectual property evaluation. In order to execute the plan in Phase II, BSI recruited the critical experts and stakeholders and obtained expert opinions and intents for the design and development to complete clinical validation of the biomarker panels for BC and CC. The two cancers together represent 26.8 % of all cancer incidences in the EU. Clinically validated results obtained in CANDLE will enable BSI to seize the business opportunity and to maximize return on investments through higher royalties.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

BSI will develop blood tests that could become blockbusters in the BC and CC diagnostic markets. The optimal expected impact of successful early diagnostics (screening) in CC and BC is the reduction of mortality and increase in cancer-free survival. Based on our projections the increase in five-year survival could reach 5-20 % depending on the cancer type.

bsi-graphics.jpg